RxDoctor Payments Data

Molly Calabria, PA

Physician Assistant · Cary, NCNPI 1942690979

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Novo Nordisk at 42.4% of the total. Reporting peaked in 2022 at $306 and has fallen 80.1% since, to $61 in 2025.

$623in general payments, 2019–2025

Across 31 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$264
  • Neurocrine Biosciences, Inc.$183
  • Lilly USA, LLC$74
  • Biohaven Pharmaceutical Holding Company Ltd.$51
  • Pfizer$33
  • Biohaven Pharmaceuticals, Inc.$18

What the payments were for

  • Food & beverage$623100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$623 in reported general payments places this provider in the 60th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$19,602
Medicare patients
145
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Rosuvastatin Calcium13$429
Atorvastatin Calcium12$77

Paid to pharmacies, not to this prescriber.

Other physician assistant in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →